Medtronic Touts 1-Year Data for VenaSeal Device

Thursday, July 2, 2015

Source: Mass Device

Medtronic (NYSE:MDT) today touted results from its VeClose clinical trial of its VenaSeal varicose vein treatment, saying the device posted a 96.8% closure rate at 12 months.

View All News »